Literature DB >> 10389851

Effects of glucose intolerance on myocardial function and collagen-linked glycation.

G F Avendano1, R K Agarwal, R I Bashey, M M Lyons, B J Soni, G N Jyothirmayi, T J Regan.   

Abstract

In experimental diabetes, diastolic dysfunction of the left ventricle has been associated with collagen-linked glycation. To determine whether less severe hyperglycemia may have similar effects, we gave alloxan to mongrel dogs (group 2) to induce impaired glucose tolerance (IGT) for comparison with normal subjects (group 1). After 6 months, hemodynamic studies were performed in the anesthetized animals. Basal heart rate, aortic pressure, and ejection fraction were comparable in the two groups, but calculated chamber stiffness was increased in group 2, associated with a reduced end diastolic volume and increased pressure. During infusion of dextran, the volume and pressure responses were similarly abnormal in group 2. In the myocardium, the collagen concentration rose with an increased interstitial distribution histologically. To assess glycation, collagen was extracted, digested with collagenase, and measured for fluorescence. Advanced glycation end products were increased in group 2 to 10.6 +/- 1.6 vs. 6.9 +/- 0.7 fluorescent units (FU)/mg collagen in group 1 (P < 0.01). To assess whether this could be pharmacologically prevented, we administered enalapril to inhibit ACE during the 6 months of glucose intolerance to group 3. This resulted in normal glycation and significant reduction in chamber stiffness increment. We gave group 4 animals aminoguanidine daily for 6 months, which prevented abnormal collagen glycation and chamber stiffness. Thus, in animals with IGT, collagen-linked glycosylation appeared to be a major factor affecting diastolic function and was shown to be amenable to pharmacological intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389851     DOI: 10.2337/diabetes.48.7.1443

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  34 in total

1.  Diabetes and Cardioplegia.

Authors:  Brittany A Potz; Laura A Scrimgeour; Jun Feng; Frank W Sellke
Journal:  J Nat Sci       Date:  2017-06

2.  Ryanodine receptor phosphorylation by CaMKII promotes spontaneous Ca(2+) release events in a rodent model of early stage diabetes: The arrhythmogenic substrate.

Authors:  Leandro Sommese; Carlos A Valverde; Paula Blanco; María Cecilia Castro; Omar Velez Rueda; Marcia Kaetzel; John Dedman; Mark E Anderson; Alicia Mattiazzi; Julieta Palomeque
Journal:  Int J Cardiol       Date:  2015-09-25       Impact factor: 4.164

Review 3.  Diabetes and the risk of heart failure.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Heart Fail Clin       Date:  2011-10-13       Impact factor: 3.179

Review 4.  Clinical modifiers for heart failure following myocardial infarction.

Authors:  Nandan S Anavekar; Nagesh S Anavekar
Journal:  Curr Heart Fail Rep       Date:  2005-12

5.  Assessment of cost and health resource utilization for elderly patients with heart failure and diabetes mellitus.

Authors:  Hillary R Bogner; Steven D Miller; Heather F de Vries; Sumedha Chhatre; Ravishankar Jayadevappa
Journal:  J Card Fail       Date:  2010-03-06       Impact factor: 5.712

Review 6.  Cardiac dysfunction and oxidative stress in the metabolic syndrome: an update on antioxidant therapies.

Authors:  Olesya Ilkun; Sihem Boudina
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.

Authors:  Susan J Zieman; David A Kass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.

Authors:  Christina Voulgari; Dimitrios Papadogiannis; Nicholas Tentolouris
Journal:  Vasc Health Risk Manag       Date:  2010-10-21

9.  Relation between aortic stiffness and left ventricular diastolic function in patients with hypertension, diabetes, or both.

Authors:  M Eren; S Gorgulu; N Uslu; S Celik; B Dagdeviren; T Tezel
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

10.  Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats.

Authors:  G Cheng; L-L Wang; L Long; H-Y Liu; H Cui; W-S Qu; S Li
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.